Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06964113 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Active, Not Recruiting Site details revised at 19 of 19 sitesv8 Show 1 more changeShow less
    • Site details revised at 19 of 19 sites
  2. Study sites: 18 to 19v7
  3. Study sites: 16 to 18v6
  4. Study sites: 15 to 16v5
  5. Study sites: 14 to 15v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date changed from estimate of Jun 30, 2025 to Jun 11, 2025 Site details revised at 9 of 14 sitesv3 Show 1 more changeShow less
    • Site details revised at 9 of 14 sites
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 13 to 14v2 Show 1 more changeShow less
    • Study sites: 13 to 14
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Biogen
92 trials monitored
See 7 trials at risk
Ulcerative Colitis
587 trials monitored
See 34 trials at risk
The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.
Trial Details
NCT Number NCT06964113
Lead Sponsor Eisai Korea Inc.
Collaborators: Gilead Sciences
Conditions Ulcerative Colitis
Enrollment 94 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov